Evidence map›Paper›PMID 36798286›Full record

ArticlebioRxiv : the preprint server for biology2023

Long COVID manifests with T cell dysregulation, inflammation, and an uncoordinated adaptive immune response to SARS-CoV-2.

Kailin Yin, Michael J Peluso, Xiaoyu Luo, Reuben Thomas, Min-Gyoung Shin, Jason Neidleman, Alicer Andrew, Kyrlia Young, Tongcui Ma, Rebecca Hoh and 20 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 57 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

30 authors at 4 institutions in 2 countries.

Kailin YinGladstone Institutes, University of California, San Francisco, USA.
Michael J PelusoDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, USA.
Xiaoyu LuoGladstone Institutes, University of California, San Francisco, USA.
Reuben ThomasGladstone Institutes, University of California, San Francisco, USA.
Min-Gyoung ShinGladstone Institutes, University of California, San Francisco, USA.
Jason NeidlemanGladstone Institutes, University of California, San Francisco, USA.
Alicer AndrewGladstone Institutes, University of California, San Francisco, USA.
Kyrlia YoungGladstone Institutes, University of California, San Francisco, USA.
Tongcui MaGladstone Institutes, University of California, San Francisco, USA.
Rebecca HohDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, USA.
Khamal AnglinDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, USA.
Beatrice HuangDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, USA.
Urania ArguetaDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, USA.
Monica LopezDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, USA.
Daisy ValdiviesoDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, USA.
Kofi AsareDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, USA.
Tyler-Marie DeveauDivision of Experimental Medicine, University of California, San Francisco, USA.
Sadie E MunterDivision of Experimental Medicine, University of California, San Francisco, USA.
Rania IbrahimDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, USA.
Ludger StändkerCore Facility Functional Peptidomics, Ulm University Medical Center, Meyerhofstrasse 1, Ulm, Germany.
Scott LuDepartment of Epidemiology and Biostatistics, University of California, San Francisco, USA.
Sarah A GoldbergDepartment of Epidemiology and Biostatistics, University of California, San Francisco, USA.
Sulggi A LeeZuckerberg San Francisco General Hospital and the University of California, San Francisco, USA.
Kara L LynchDivision of Laboratory Medicine, University of California, San Francisco, USA.
J Daniel KellyDepartment of Epidemiology and Biostatistics, University of California, San Francisco, USA.
Jeffrey N MartinDepartment of Epidemiology and Biostatistics, University of California, San Francisco, USA.
Jan MünchCore Facility Functional Peptidomics, Ulm University Medical Center, Meyerhofstrasse 1, Ulm, Germany.
Steven G DeeksDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, USA.
Timothy J HenrichDivision of Experimental Medicine, University of California, San Francisco, USA.
Nadia R RoanGladstone Institutes, University of California, San Francisco, USA.
University of California, San Francisco · USGladstone Institutes · USUniversität Ulm · DESan Francisco General Hospital · US

Funding

Research BaseP30DK063720 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GERMAN, MICHAEL S · 2003 to 2019
$21.8M
Targeting Non Viral Markers of HIV PersistenceR01AI141003 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HENRICH, TIMOTHY JENSEN · 2018 to 2022
$4.9M
Evaluation of the Interplay between HIV and COVID-19 in a large urban safety-net HIV clinicR01AI158013 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GANDHI, MONICA, SPINELLI, MATTHEW A. · 2020 to 2023
$3.1M
Characterizing the virologic and immunologic signatures of HIV exceptional controlK23AI157875 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PELUSO, MICHAEL JOSEPH · 2021 to 2025
$927k
Understanding the epidemiology and natural history of unrecognized Ebola virus infectionK23AI146268 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KELLY, JOHN DANIEL · 2019 to 2022
$748k
UCSF DVS CyTOF Mass CytometerS10OD018040 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LANIER, LEWIS LEE · 2014 to 2014
$600k
BD FACSAria II Flow CytometerS10RR028962 · NCRR · J. DAVID GLADSTONE INSTITUTES · PI CAVROIS, MARIELLE · 2011 to 2011
$544k
NCRR NIH HHS S10 RR028962NIAID NIH HHS K23 AI146268NIAID NIH HHS K23 AI157875NIAID NIH HHS L30 AI126521NIAID NIH HHS L30 AI147159NIAID NIH HHS R01 AI141003NIAID NIH HHS R01 AI158013NIDDK NIH HHS P30 DK063720NIH HHS S10 OD018040
6 · The paper itself

Abstract

Long COVID (LC), a type of post-acute sequelae of SARS-CoV-2 infection (PASC), occurs after at least 10% of SARS-CoV-2 infections, yet its etiology remains poorly understood. Here, we used multiple "omics" assays (CyTOF, RNAseq/scRNAseq, Olink) and serology to deeply characterize both global and SARS-CoV-2-specific immunity from blood of individuals with clear LC and non-LC clinical trajectories, 8 months following infection and prior to receipt of any SARS-CoV-2 vaccine. Our analysis focused on deep phenotyping of T cells, which play important roles in immunity against SARS-CoV-2 yet may also contribute to COVID-19 pathogenesis. Our findings demonstrate that individuals with LC exhibit systemic inflammation and immune dysregulation. This is evidenced by global differences in T cell subset distribution in ways that imply ongoing immune responses, as well as by sex-specific perturbations in cytolytic subsets. Individuals with LC harbored increased frequencies of CD4+ T cells poised to migrate to inflamed tissues, and exhausted SARS-CoV-2-specific CD8+ T cells. They also harbored significantly higher levels of SARS-CoV-2 antibodies, and in contrast to non-LC individuals, exhibited a mis-coordination between their SARS-CoV-2-specific T and B cell responses. RNAseq/scRNAseq and Olink analyses similarly revealed immune dysregulatory mechanisms, along with non-immune associated perturbations, in individuals with LC. Collectively, our data suggest that proper crosstalk between the humoral and cellular arms of adaptive immunity has broken down in LC, and that this, perhaps in the context of persistent virus, leads to the immune dysregulation, inflammation, and clinical symptoms associated with this debilitating condition.

Identifiers

PMID36798286
PMCPMC9934605
OpenAlexW4319870037

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.